Fortis Healthcare Ltd News

Fortis Healthcare Q2 profit up 5%, revenue rises 12% on strong hospital biz

The company's revenue from operations rose to Rs 1,988 crore in Q2 FY25, a 12.3 per cent Y-o-Y increase from Rs 1,770 crore reported in Q2 FY24

Fortis Healthcare gets CCI nod to acquire stake in Agilus Diagnostics

The competition watchdog CCI on Tuesday approved Fortis Healthcare's proposal to acquire an additional 31.52 per cent stake in Agilus Diagnostics. Multi-speciality hospital chain Fortis Healthcare Ltd (FHL) is engaged in providing integrated healthcare delivery services like medicare, healthcare and diagnostics. The diagnostics services business of FHL is being undertaken primarily through Agilus. "Commission approves the acquisition of additional 31.52 per cent share capital of Agilus Diagnostics Ltd by Fortis Healthcare Ltd," according to a post by CCI on X. After the transaction, the shareholding of Fortis Healthcare Ltd (FHL) in Agilus will increase from 57.68 per cent to 89.2 per cent. In August, Fortis Healthcare announced that it will acquire a 31 per cent stake in Agilus Diagnostics for Rs 1,780 crore valuing Agilus at Rs 5,700 crore. The Competition Commission of India (CCI) has also cleared the proposed merger of Diliigent Power into DB Power, and the reorganisation of

Fortis Health hits 52-week high on plans to buy 32% stake in subsidiary

Fortis Healthcare's stock price today surged after the healthcare company said that it will buy the entire 31.52 per cent stake held by private equity investors in the material wholly owned subsidiary

Fortis Healthcare to acquire 31% stake in Agilus for Rs 1,780 crore

Deal values diagnostic arm at Rs 5,700 crore

Fortis Healthcare Q1 results: Profit rises 40% over hospital biz growth

The company's revenue from operations rose to Rs 1,859 crore in Q1FY25, a 12.2 per cent Y-o-Y rise from Rs 1,657 crore reported in Q1FY24

Nomura ups target price for Fortis, sees 12% upside; reiterates 'Buy'

The global brokerage firm maintained its 'Buy' call for Fortis Healthcare with an updated twelve month forward target price of Rs 547, a 12 per cent upside to Monday's close